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Abstract 
 
OBJECTIVE: The objective of this evidenced based medicine review is to determine whether 
or not botulinum toxin A injections into the pelvic floor muscles of women with chronic 
genitopelvic pain and vaginal spasm improve pain and sexual functioning. 
 
STUDY DESIGN: Review of two double blind randomized controlled trials and one case series 
from peer reviewed journals published between 2006-2011. 
 
DATA SOURCES: Two randomized controlled trials and one case series were found using 
PubMed, Google Scholar, and Cochrane Library.  
 
OUTCOMES MEASURED: All three studies measured pain and sexual functioning using self-
reported surveys including the visual analog scale for pain, Female Sexual Functioning Index, 
and Sexual Activity Questionnaire.  
 
RESULTS: Petersen et al. determined that botulinum toxin injections into the vulva did not 
improve pain or sexual functioning in vestibulodynia patients when compared to the control 
group. Similarly, Abbott et al. found that botulinum toxin injections into the pelvic muscles for 
chronic pelvic pain did not improve pain or sexual functioning when compared to the control 
group. In the case series conducted by Pelletier et al., botulinum toxin injections into the vulva 
reduced pain and improved sexual functioning for vestibulodynia patients.  
 
CONCLUSION: Botulinum toxin type A injections into the pelvic floor muscles are not an 
effective form of treatment for chronic pelvic pain or vestibulodynia. Both randomized 
controlled trials contributed the improvement in the control group to the placebo effect, among 
other theories. In the future, randomized controlled trials should use a larger sample size and 
include a nocebo group to further elaborate on the above results.   
 
KEY WORDS: Provoked Vestibulodynia, Botulinum Toxin, Chronic Pelvic Pain 
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INTRODUCTION 
Chronic pelvic pain is defined as noncyclic pain localized to the genitopelivc area for 
greater than three months that causes the patient functional disability and is not related to 
pregnancy.1 Common symptoms of chronic pelvic pain are muscular spasm and dyspareunia.1 
Chronic pelvic pain is a broad term and is commonly found to be a symptom of an underlying 
pathologic condition. The various causes of chronic pelvic pain including endometriosis, 
adenomyosis, pelvic inflammatory disease, irritable bowel syndrome, interstitial cystitis, and 
depression, are too numerous to discuss for the purposes of this paper.1 For simplicity, provoked 
vestibulodynia, a condition that can cause chronic pelvic pain, will be discussed. Vestibulodynia, 
otherwise known as vulvodynia, is chronic vulvar pain in women for greater than three months.2 
Provoked vestibulodynia refers to pain and spasm in the vulva and vagina after physical 
aggravation of the tissue, such as through tampon insertion or sexual intercourse.2 
The prevalence of chronic vulvar pain is between 3-15%.2 That number rises to 39% 
when considering chronic genitopelvic pain in women.1 The prevalence of dyspareunia, one of 
the most common presenting symptoms of provoked vestibulodynia, is between 8-22%.3 Having 
to care for patients with vestibulodynia, chronic pelvic pain, or dyspareunia in practice is 
therefore quite possible. Alarmingly, reports have indicated that half of women with self-
reported vulvar pain and two thirds of females with chronic pelvic pain will not seek medical 
attention, indicating prevalence may be under-reported.1,2 It is vital that members of the medical 
community remember to ask patients questions concerning these conditions during routine 
primary care or gynecological visits. However, those patients who do seek medical attention are 
having a significant impact on health care expenses. One study estimated that chronic 
genitopelivc pain cost the United States health care system 881.5 million dollars per year in 
Broadbent, Botulinum Injections for Pelvic Pain, 2 
terms of outpatient visits alone.4 In this instance, discussing financial burden on the patient is 
appropriate, as well. Botulinum toxin injections for genitopelivc pain syndromes, including 
provoked vestibulodynia, are considered off-label uses.2 Typically, the injections will be a direct 
out-of-pocket expense to the patient.2 No documented number of vestibulodynia or chronic 
pelvic pain health care visits could be found for the purposes of this research paper.  
The exact cause of provoked vestibulodynia is not known. One proposed theory is that 
pain in the vulva is generated as a result of compression of blood vessels and nerve fibers from 
pelvic floor hypertonicity and spasm.4 An initial insult to the vulva causes an overactive 
inflammatory response leading to proliferation of nerve fibers and central sensitization of pain.2 
Overactive nerves release excessive amounts of acetylcholine, causing hypertonicity and spasm.4 
Other proposed theories include infection with C. albicans, vaginal allergy, hormone imbalance, 
genetic predisposition, and psychological dysfunction.2 Notably, there is an association between 
provoked vestibulodynia and other hypersensitive pain syndromes, like irritable bowel syndrome 
and fibromyalgia.2  
Diagnosis of provoked vestibulodynia is based on four factors: pain localized to the 
vulva, without identifiable cause, that has been present for greater than three months, and is 
worsened by pressure point testing.2 A detailed history and physical, including inspection, 
palpation, speculum exam, and pressure point testing using a cotton-tipped applicator, are 
required for proper diagnosis.2 Laboratory testing and diagnostic imaging should be done as 
needed to rule out identifiable causes.  
Several treatments exist for vestibulodynia. Behavior modification, including proper 
vulvar hygiene, and pelvic floor physical therapy are mainstays of treatment encouraged in all 
patients.5 Cognitive behavioral therapy, topical lidocaine, and topical estradiol are considered 
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first line management.5 Second tier therapy consists of anti-depressants and neuropathic pain 
agents.5 Third tier treatment includes botulinum toxin injections, steroid injections, and 
gabapentin cream.5 Surgical intervention is last line therapy for severe cases of vestibulodynia 
refractory to the above-mentioned treatment options.5  
Botulinum toxin type A is a relatively new treatment for vestibulodynia. The toxin 
relaxes hyperactive muscles by inhibiting exocytosis of acetylcholine, leading to muscle 
paralysis.4 Blood flow to the tissue improves, lessening painful stimuli.4 Botulinum toxin is 
believed to have some initial analgesic effect, as well, until paralysis is reached in approximately 
2-3 days.4 This paper will evaluate the efficacy of botulinum toxin type A injections into the 
pelvic floor muscles of women with provoked vestibulodynia, and chronic genitopelivc pain, as 
an alternative treatment modality.  
OBJECTIVE 
The objective of this evidenced based medicine review is to determine whether or not 
botulinum toxin A injections into the pelvic floor muscles of women with chronic genitopelvic 
pain and vaginal spasm improve pain and sexual functioning. 
METHODS 
 Three studies on the use of botulinum toxin type A injections as a treatment for provoked 
vestibulodynia and chronic pelvic pain in women greater than the age of 18 were selected for 
analysis. Petersen et al. and Abbott et al. are both double-blind, randomized controlled trials, 
while Pelletier et al. is classified as a case series. All three articles were published in English in 
peer-reviewed journals between 2006-2011. To find the above articles, key words “botulinum 
toxin,” “provoked vestibulodynia,” and “chronic pelvic pain” were searched in PubMed, Google 
Scholar, and Cochrane Library databases. Only relevant double-blind randomized controlled 
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trials that answered the above stated clinical question were included in the initial search. After 
only two relevant randomized controlled trials were found, the search was broadened to include 
non-randomized, non-controlled studies. A subsequent case series was found that was relevant to 
the proposed clinical question. Inclusion criteria for this analysis consisted of relevance to the 
clinical question and whether or not patient oriented outcomes were measured. Studies were 
excluded if outcomes measured were not patient oriented. Statistics utilized in the above studies 
include: number needed to treat (NNT), p-values, and mean change from baseline.  
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Table 1: Demographics and characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Petersen, 
20096 
Double 
Blind 
RCT 
64 >18 
years 
old 
symptoms of 
provoked 
vestibulodynia for 
more than 6 
months; diagnosis 
of provoked 
vestibulodynia 
according to 
Friedrisch criteria; 
ability to read and 
understand Danish 
language; use of 
safe contraception 
(oral 
contraceptives, 
intrauterine device, 
Nuvaring®) 
sterilization, or 
hysterectomy for 
the first 6 months 
after inclusion 
treatment (barrier 
methods were not 
acceptable forms 
of safe 
contraception) 
previous treatment with 
Botox in the genitalia; 
ongoing infection in the 
vulva or pelvis; skin 
disease in the vulva; 
pregnancy; major 
medical or psychiatric 
illness (diagnosed with 
depression, and/or in 
medical treatment for 
depression of 
schizophrenia); 
peripheral motor 
neurological disease 
(myasthenia gravis, 
amyotrophic lateral 
sclerosis, or Lambert-
Eaton syndrome); 
diabetes; use of 
calcium-antagonists, 
aminoglycosides, 
magnesium sulfate, or 
systemic or topical 
steroids; concurrent 
medical, physical, 
psychological, or sexual 
therapy within the first 
6 months of their 
participation in this 
study; age less than 18 
4 .5 mL of solution 
(20 units of 
botulinum toxin A 
diluted in saline) 
injected 
symmetrically into 
the 
bulbospongiosus 
muscles lateral to 
the meatus of the 
Bartholin’s’ duct 
 
Abbott, 
20067 
Double 
Blind 
RCT 
60 18-55 
years 
old 
female aged 18-55; 
2 years of chronic 
pelvic pain that has 
disrupted daily 
activities; objective 
evidence of pelvic 
floor myalgia 
defined as the 
presence of 
contracted, painful 
muscles on 
palpation and 
elevated resting 
pressures (more 
than 40cm H2O) 
by vaginal 
manometry 
inability to demonstrate 
pelvic floor spasm; 
breastfeeding, pregnant, 
or desire to become 
pregnant; unwilling to 
use contraception 
during the study; 
previous botulinum 
toxin A injections into 
the pelvic floor; 
palpable pelvic 
pathology; current use 
of aminoglycoside 
antibiotics; history of 
neurologic bleeding 
disorders; known 
sensitivity to botulinum 
toxin A 
3 1mL solution (20 
units botulinum 
toxin A diluted in 
saline) injected 
into two sites 
bilaterally within 
each puborectalis 
and 
pubococcygeus 
muscles under 
conscious sedation  
 
Pelletier, 
20118 
Case 
Series 
20 18-60 
years 
old  
patients’ refractory 
to other forms of 
treatment for 
vulvodynia (TCAs, 
biofeedback, 
counseling); pain 
triggered by 
nonallergic 
stimulus that is 
responsible for 
introital 
dyspareunia; post-
menopausal or 
taking an effective 
form of 
contraception 
positive 
serological 
evidence for 
HIV or 
Chlamydia 
trachomatis 
0 1mL solution (50 
units of botulinum 
toxin A diluted in 
saline) injected 
into the right and 
left 
bulbospongiosus 
muscles under 
EMG monitoring  
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OUTCOMES MEASURED 
 Pain and sexual functioning were the patient-oriented outcomes measured in each of the 
three articles. Pain was measured in all three studies using the visual analog scale (VAS). 
Participants choose a number between 1-10 that best reflects their pain level, ‘0’ indicating no 
pain and ‘10’ indicating intensely severe pain. Pelletier et al. assessed pain prior to the botulinum 
injections and then re-assessed at 3 and 6 months post-injection.8 Petersen et al. assessed 
similarly, but included re-assessment at 12 months, as well.6 Abbott et al. re-assessed at 2, 4, 8, 
12, 16, 20, and 26 weeks post-injection.7  
Two questionnaires were utilized to assess sexual functioning. Petersen et al. and 
Pelletier et al. used the Female Sexual Functioning Index (FSFI). This is a self-report survey 
where females answer 19 questions about their sexual functioning over the past 4 weeks. 
Questions cover six main categories: desire, arousal, lubrication, orgasm, satisfaction, and pain. 
Responses are rated from 0-5 or 1-5 and added together. The cut off is a score <26, which 
indicates a risk for sexual dysfunction. The higher the score, the less likely a female is 
experiencing sexual dysfunction. Again, Pelletier et al. and Petersen et al. assessed sexual 
functioning before the injections were given and used the same time frame listed above for re-
assessment post-injection.6,8 Abbott et al. used a Sexual Activity Questionnaire (SAQ) to 
measure sexual functioning.7 Participants answer questions using the 4-point Likert scale9 on 
sexual function in relation to pleasure, discomfort, and habit.7 Responses allowed researchers to 
quantify how many women were experiencing or not experiencing certain sexual issues. 
Questionnaires were completed before the injections were given and then again at 4, 12, 16, 20, 
and 26 weeks post-injection.7  
RESULTS 
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 Two randomized controlled trials and one case series concerning the use of botulinum 
toxin type A as a novel treatment option for women greater than 18 years old with provoked 
vestibulodynia or chronic pelvic pain were analyzed for the purpose of this paper. All studies 
took place in outpatient gynecology settings.6,7,8  
Petersen et al. began their study by screening 164 women using the inclusion criteria 
listed in Table 1.6 Originally, 65 women were included in the study, but one participant was 
excluded on the day of the injections for an active vulvar infection.6 Women were randomly 
assigned to either the botulinum toxin group (B group) or the placebo group (P group).6  
In terms of pain reduction, there was no significant difference reported between the two 
groups at 6 months follow up (p>0.05).6 However, there was a significant difference in pain 
reduction at 6 months within each group.6 The mean change from baseline for the B group at 6 
months follow up was -2.3 (p<0.001), while the P group was -2.5 (p<0.001).6 At baseline, 89% 
of patients in the B group and 100% of patients in the P group scored below at 26.55 on the 
FSFI, indicating sexual dysfunction.6 At 6 months, scores improved with researchers reporting a 
mean change from baseline of -10% in the B group and -14% in the P group.6 The improvement 
in sexual functioning was not significant between the two groups (p=0.635).6 Sexual activity was 
used as a means to assess the efficacy of the botulinum toxin injections, as well.6 The researchers 
reported their findings as dichotomous data, and therefore NNT could be calculated using the 
information in Tables 2 and 3. The NNT to allow sexual activity in patients abstaining from 
sexual activity because of provoked vestibulodynia was -5.6 This means that for every 5 women 
treated with botulinum toxin for provoked vestibulodynia, 1 fewer woman would be sexually 
active than when compared to placebo.6 This data was found to be significant (p=0.022), and to 
have a large treatment effect, as only 64 women were enrolled in the study.6 
Broadbent, Botulinum Injections for Pelvic Pain, 8 
In total, four women were lost of follow up during the study: two were excluded at 3 
months for topical lidocaine use, one withdrew at 4 months, and one was excluded at 5 months 
due to pregnancy.6 Adverse events reported by participants included tenderness at the injection 
site, flu-like symptoms lasting 12-24 hours post-injection, muscle weakness, and issues 
achieving orgasm.6 
Table 2: Participants sexually active at 6 months, Petersen et al.6 
 Botulinum toxin 
group 
Placebo group p-value 
% sexually active at 6 
months follow up 
83% 100% 0.022 
 
Table 3: Calculations for Petersen et al.6 
Relative benefit increase 
(RBI) 
Absolute benefit increase 
(ABI) 
Number needed to treat 
(NNT) 
-0.17 -0.17 -5 
 
Abbott et al. began their study by screening 401 potential participants over the phone.7 In 
total, 118 women were assessed, and 60 women met the criteria to participate in the study.7 They 
were subsequently randomized into two groups, the Botulinum toxin (BOTOX) group and the 
placebo group.7  
Again, there was no significant difference in VAS scores when compared to the placebo 
group at the conclusion of the study.7 However, VAS scores did decrease for both groups 
throughout the follow up process.7 Results from the SAQ are listed in Tables 4 and 5. No 
significant mean change from baseline was reported between the BOTOX group when compared 
to control for each section of the SAQ.7 There was no significant mean change from baseline 
within each group either.7 
In total, one woman was lost to follow up and two women withdrew from the study.7 
Reported adverse events included: cold/flu-like symptoms, bleeding at the injection site, 
headache, pelvic/back pain, and gastrointestinal upset.7 Events occurred in both groups.7 
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Notably, two members of the BOTOX group experienced urinary and fecal incontinence after the 
injections, which slowly resolved over a few months.7  
Table 4: Mean change in SAQ responses, BOTOX group, Abbott et al.7 
SAQ sections BOTOX group 
at baseline 
BOTOX group 
at 26 weeks 
Mean change 
from baseline 
p-value 
Pleasure 9 11.5 +1.5 Not significant 
Habit 1 1 0 Not significant  
Discomfort  3 2 -1 Not significant  
 
Table 5: Mean change in SAQ responses, Placebo group, Abbott et al.7 
SAQ sections Placebo group 
at baseline 
Placebo group 
at 26 weeks 
Mean change 
from baseline 
p-value 
Pleasure 8 10 +2 Not significant 
Habit 1 1 0 Not significant 
Discomfort 5 2 -3 Not significant 
 
Pelletier et al. enrolled 20 women with provoked vestibulodynia.8 As reported in Table 6, 
a significant number of women were able to have sexual intercourse at 3 months when compared 
to baseline.8 Mean change from baseline in both VAS and FSFI scores, as reported in Table 7, 
were also found to be significant when compared to baseline.8 Authors reported no adverse 
effects from the botulinum toxin treatment except pain at the injection site and flu-like symptoms 
post-injection.8  
Table 6: Participants able to have sexual intercourse, Pelletier et al.8 
Sexual intercourse possible 
at baseline (N, %) 
Sexual intercourse possible 
at 3 months (N, %) 
p-value 
2, 10% 13, 65% <0.001 
 
Table 7: Mean change in VAS and FSFI scores, Pelletier et al.8 
 Baseline 3 months Mean change from baseline p-value 
Average VAS 
score 
8.37 2.57 -4.47 <0.001 
Average FSFI 
score 
3.74 18.44 +16.42 <0.001 
 
DISCUSSION 
Broadbent, Botulinum Injections for Pelvic Pain, 10 
 Both randomized controlled trials concluded that botulinum toxin injections produced no 
significant changes in pain or sexual functioning when compared to the control group.6,7 
However, the experimental and control groups in both studies documented improvement in pain 
and sexual functioning scores throughout the follow up process.6,7 Petersen et al. attributed the 
improvement of the control group to placebo effect and postulated that the success of various 
case series might be due to this, as well.6 Alternatively, the natural progression of the disease 
may lead to improvement overtime, which is potentially why both groups improved in a similar 
fashion.6 Abbott et al. agreed that the placebo effect could be why no significant changes are 
noted between groups, but also hypothesized that improvement in the control group could be due 
to the effects of muscle needling.7 Injections into the muscle with saline could have desensitized 
trigger points, leading to decreased muscle spasm and pain, similar to the effects of 
acupuncture.7 The case series by Pelletier et al., however, reported significant improvement in 
pain and sexual functioning among participants.8  
 Still, limitations exist in the above three studies, including the relatively small sample 
size used by all.6,7,8 Petersen et al. admit that the low dosage of botulinum toxin used in their trial 
and the lack of evaluation of pelvic floor tonus were issues present in the study design.6 Also, 
56% of participants were taking OCPs throughout the study and the affect the additional 
hormones could have had on the outcomes is uncertain.6 Abbott et al. was unclear about how 
questionnaires were scored and was limited in their discussion of the results leaving much of the 
analysis to the reader.7 Pelletier et al. only had fifteen women fill out the FSFI and never 
commented on why five women were excluded from analysis.8  
 Botulinum toxin injections, as reported above, are not typically covered by insurance 
companies.2 Not only are injections typically paid for by the patient but locating a practitioner 
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who will perform the injections is also difficult.2 Adverse effects of botulinum toxin injections 
into the pelvis are not well documented, either. Flu-like illness, weakness, bruising or bleeding at 
the injection site, transient numbness, headache, and malaise are some potential side effects.10 
Considering this and the data from the above randomized controlled trials that indicate 
botulinum toxin injections into the pelvis do not improve pain or sexual functioning, 
practitioners should not recommend this line of treatment for patients with provoked 
vestibulodynia.  
CONCLUSION 
As evidenced above, botulinum toxin type A injections into the pelvic floor muscles are 
not an effective form of treatment for chronic pelvic pain or vestibulodynia. However, very few 
randomized controlled trials exist concerning the use of botulinum toxin injections for 
genitopelivc pain syndromes. Continuing to study the use of botulinum toxin as a treatment 
option is therefore vital. Using larger sample sizes, higher concentrations of botulinum toxin, and 
studying objective evidence of pelvic floor pain and spasm will improve the quality of data 
produced by future studies. Using a standardized technique to deliver the injections will allow 
easier comparison between research studies, as well. Lastly, further research into acupuncture 
and trigger point release as treatment options for chronic pelvic pain and provoked 
vestibulodynia could prove beneficial to patients in the future. 
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